IgA Nephropathy

A review and meta-analysis revealed an association between crescents and worsened renal outcomes in patients with IgAN.

IgAN treated with long-term corticosteroids may lead to adverse outcomes and increased clinical burden.

We spoke with George Edward Newman, MD, a site principal investigator of the PREVAIL study of felzartamab in IgAN.

Phase 3 VISIONARY trial data showed sibeprenlimab helps achieve significant proteinuria reduction in IgAN.

Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.

Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.

Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.

Long-term data demonstrated that zigakibart reduced proteinuria and stabilized kidney function of patients with IgAN.

Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.

A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.

Knowledge Hubs